



Seventure Partners announces the trade sale of its portfolio company Cambrooke Therapeutics, Inc. to Ajinomoto Co. Inc

Paris, France – 10 November 2017 – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces the trade sale of its portfolio company Cambrooke Therapeutics Inc (Cambrooke), MA, US, to Ajinomoto Co. Inc. (Ajinomoto). This represents the first transactional exit from Seventure’s healthcare and nutrition-focused investment vehicle, *Health For Life Capital™*.

Cambrooke is a global leader and innovator in therapeutic nutrition for inborn errors of metabolism and ketogenic diet. Cambrooke’s product portfolio serves the needs of people with chronic health conditions, who are reliant on Medical Foods and specialized functional foods as a central component of their daily nutritional needs. With this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise and will continue leading the field of therapeutic nutrition solutions for chronic health conditions. It will also be able to continue serving its customers’ lifestyle needs, now with expanded reach and R&D capabilities.

Cambrooke President and Chief Executive Officer Howard Lossing states that “Ajinomoto is a worldwide leader in amino acids, pharmaceuticals, high-quality seasonings, processed foods, beverages, and specialty chemicals. Ajinomoto’s corporate motto of ‘Eat Well, Live Well.’ is an elegant statement that directly reflects Cambrooke’s mission of improving lives via providing the most delicious and most nutritious Medical Foods for people with chronic health conditions.”

Seventure Partners have led the latest investment round into Cambrooke, joined by returning backers Galen Partners and has leveraged its extensive industry knowledge and expertise to support company international and product portfolio expansion efforts.

Isabelle de Cremoux, CEO of Seventure Partners and founder of “*Health for Life Capital™*” states: “*Health for Life Capital™*’s continued success, as realized by Cambrooke’s trade sale, generating an IRR of over 55% for this transaction, has shown the value of a highly specialized nutrition and healthcare investment vehicle. We are delighted for Cambrooke and look forward to seeing the Company’s continued success.”

Oxana Kukhaneva, venture partner at Seventure Partners adds: “We are pleased to partner with Ajinomoto Inc on this acquisition, as it allows us not only to demonstrate solid financial returns but also to ensure the continuity of Cambrooke’s mission in delivering the best of the care to its customers with chronic health conditions and pushing further the boundaries of innovation in its segment.”

-ENDS-

Notes to Editors

About The Microbiome

The microbiome, which consists in all the micro-organisms that reside in and on the human body, is an exciting and fast-developing new field at the interface of pharmaceuticals and nutrition, offering abundant opportunities for developing new medicines. The composition and functionality of the bacterial ecosystem forming a large part of the microbiome, in the gut and elsewhere, has been linked to various health conditions, among which acne, psoriasis and allergies, gastrointestinal ailments, Crohn disease, obesity, diabetes, autism, depression or cancer. There are approximately 10 times more bacteria than human cells in the body, and over a hundred times more bacterial genes than human ones. The multitude of biological processes and indications affected by the bacterial ecosystem within the human microbiome, makes its balance critical to health. Understanding and maintaining an adequate balance of species within this complex ecosystem is an important goal for future medical progress, especially in the area of preventing and treating chronic diseases.

About Seventure Partners

With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe, Israel and North America.

In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched *Health for Life Capital™* which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis, as well as entrepreneurs and financial institutions.

For more details: <http://www.seventure.fr/en/> Twitter [@SeventureP](https://twitter.com/SeventureP)

About Health For Life Capital™

Seventure Partners launched *Health for Life Capital™*, the first venture capital fund focused mainly on investments in the microbiome and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Israel and Asia. The €160m fund attracted strategic investments from prestigious organisations including Danone, Novartis, Tereos, Tornier, Lesaffre and Bel, as well as financial institutions and entrepreneurs. *Health for Life Capital™* is managed by Seventure's Life sciences team.

For more details: <http://www.seventure.fr/en/>

About Cambrooke Therapeutics

Founded in 2000, Cambrooke, a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious chronic unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy.

More information is available at <http://www.cambrooke.com/>

About Ajinomoto North America, Inc.

Ajinomoto North America, Inc. is a wholly owned subsidiary of Ajinomoto Co., Inc. Ajinomoto is recognized as a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries, as well as food ingredients.

For additional information on Ajinomoto North America, Inc., please visit www.ajinorthamerica.com.

Media contacts:		
<i>At the Company</i> Isabelle de Cremoux CEO and Managing Partner of Seventure Partners Tel: + 33 1 58 19 22 77 Email: isabelle.decremoux@seventure.fr	<i>In France</i> Agence Yucatan Caroline Prince-Albagnac Tel: +33 1 53 63 27 35 Email: cprince@yucatan.fr	<i>International</i> Instinctif Partners Sue Charles/ Gemma Harris Tel: +44 20 7866 7860 Email: seventure@instinctif.com